Login to Your Account


PERTH, Australia – Following its IPO in August, Melbourne-based Adalta Pty Ltd. inked two deals this month, and is now moving to the clinic with its human version of the shark antibody platform, the i-body.

Privately held Arog Pharmaceuticals Inc. won orphan drug status in Europe for crenolanib to treat AML and soft-tissue sarcoma.

Gigagen Inc. is a small company seeking to harness the power of genetic material, as its name implies, by the millions.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: